Oncology Today with Dr Neil Love

Featuring an interview with Prof Andreas Hochhaus, including the following topics:
Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
Potential mechanisms of adverse events documented with TKIs (10:23)
Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
Comparative efficacy of asciminib and other agents used to treat CML (40:01)
Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
Practical care strategies for CML patients; future developments (52:32)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:
Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00)
Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03)

CME information and select publications

Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics:
Introduction (0:00)
Best Option for Your Patient (1:28)
Biological Considerations (6:26)
KRAS G12C Inhibitors (11:33)
Second-Line Treatment (13:02)
Current Clinical Trials in the First-Line Metastatic Setting (32:18)
Current Clinical Trials in the Localized Setting (49:52)
Current Clinical Trials with New Treatment Combinations and Agents (53:51)

CME information and select publications

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:
Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)
Nonmetastatic Disease (10:32)
Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50)

CME information and select publications

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications